vs

Side-by-side financial comparison of DNOW Inc. (DNOW) and Revvity (RVTY). Click either name above to swap in a different company.

DNOW Inc. is the larger business by last-quarter revenue ($959.0M vs $772.1M, roughly 1.2× Revvity). Revvity runs the higher net margin — 12.7% vs -16.8%, a 29.5% gap on every dollar of revenue. On growth, DNOW Inc. posted the faster year-over-year revenue change (68.0% vs 5.9%). Revvity produced more free cash flow last quarter ($161.8M vs $76.0M). Over the past eight quarters, DNOW Inc.'s revenue compounded faster (30.5% CAGR vs 9.0%).

DNOW Inc., operating under the trade name DistributionNOW, is a global industrial and energy products distributor. It provides supply chain management, inventory optimization, and technical support services, offering parts, equipment, and consumables for oil and gas, renewable energy, manufacturing, and construction sectors, with operations spanning North America, Europe, and Asia-Pacific.

Revvity, Inc. is an American company in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines.

DNOW vs RVTY — Head-to-Head

Bigger by revenue
DNOW
DNOW
1.2× larger
DNOW
$959.0M
$772.1M
RVTY
Growing faster (revenue YoY)
DNOW
DNOW
+62.1% gap
DNOW
68.0%
5.9%
RVTY
Higher net margin
RVTY
RVTY
29.5% more per $
RVTY
12.7%
-16.8%
DNOW
More free cash flow
RVTY
RVTY
$85.8M more FCF
RVTY
$161.8M
$76.0M
DNOW
Faster 2-yr revenue CAGR
DNOW
DNOW
Annualised
DNOW
30.5%
9.0%
RVTY

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DNOW
DNOW
RVTY
RVTY
Revenue
$959.0M
$772.1M
Net Profit
$-161.0M
$98.4M
Gross Margin
5.2%
Operating Margin
-19.6%
14.5%
Net Margin
-16.8%
12.7%
Revenue YoY
68.0%
5.9%
Net Profit YoY
-905.0%
3.9%
EPS (diluted)
$-1.42
$0.86

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DNOW
DNOW
RVTY
RVTY
Q4 25
$959.0M
$772.1M
Q3 25
$634.0M
$698.9M
Q2 25
$628.0M
$720.3M
Q1 25
$599.0M
$664.8M
Q4 24
$571.0M
$729.4M
Q3 24
$606.0M
$684.0M
Q2 24
$633.0M
$691.7M
Q1 24
$563.0M
$649.9M
Net Profit
DNOW
DNOW
RVTY
RVTY
Q4 25
$-161.0M
$98.4M
Q3 25
$25.0M
$46.7M
Q2 25
$25.0M
$53.9M
Q1 25
$22.0M
$42.2M
Q4 24
$20.0M
$94.6M
Q3 24
$13.0M
$94.4M
Q2 24
$24.0M
$55.4M
Q1 24
$21.0M
$26.0M
Gross Margin
DNOW
DNOW
RVTY
RVTY
Q4 25
5.2%
Q3 25
22.9%
53.6%
Q2 25
22.9%
54.5%
Q1 25
23.2%
56.5%
Q4 24
22.6%
Q3 24
22.3%
56.3%
Q2 24
21.8%
55.7%
Q1 24
22.9%
54.6%
Operating Margin
DNOW
DNOW
RVTY
RVTY
Q4 25
-19.6%
14.5%
Q3 25
5.2%
11.7%
Q2 25
5.1%
12.6%
Q1 25
5.0%
10.9%
Q4 24
4.4%
16.3%
Q3 24
3.8%
14.3%
Q2 24
5.2%
12.4%
Q1 24
5.0%
6.8%
Net Margin
DNOW
DNOW
RVTY
RVTY
Q4 25
-16.8%
12.7%
Q3 25
3.9%
6.7%
Q2 25
4.0%
7.5%
Q1 25
3.7%
6.4%
Q4 24
3.5%
13.0%
Q3 24
2.1%
13.8%
Q2 24
3.8%
8.0%
Q1 24
3.7%
4.0%
EPS (diluted)
DNOW
DNOW
RVTY
RVTY
Q4 25
$-1.42
$0.86
Q3 25
$0.23
$0.40
Q2 25
$0.23
$0.46
Q1 25
$0.20
$0.35
Q4 24
$0.19
$0.77
Q3 24
$0.12
$0.77
Q2 24
$0.21
$0.45
Q1 24
$0.19
$0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DNOW
DNOW
RVTY
RVTY
Cash + ST InvestmentsLiquidity on hand
$164.0M
$919.9M
Total DebtLower is stronger
$411.0M
Stockholders' EquityBook value
$2.2B
$7.3B
Total Assets
$3.9B
$12.2B
Debt / EquityLower = less leverage
0.18×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DNOW
DNOW
RVTY
RVTY
Q4 25
$164.0M
$919.9M
Q3 25
$266.0M
$931.4M
Q2 25
$232.0M
$991.8M
Q1 25
$219.0M
$1.1B
Q4 24
$256.0M
$1.2B
Q3 24
$261.0M
$1.2B
Q2 24
$197.0M
$2.0B
Q1 24
$188.0M
$1.7B
Total Debt
DNOW
DNOW
RVTY
RVTY
Q4 25
$411.0M
Q3 25
Q2 25
Q1 25
Q4 24
$0
Q3 24
Q2 24
Q1 24
Stockholders' Equity
DNOW
DNOW
RVTY
RVTY
Q4 25
$2.2B
$7.3B
Q3 25
$1.2B
$7.4B
Q2 25
$1.2B
$7.6B
Q1 25
$1.1B
$7.6B
Q4 24
$1.1B
$7.7B
Q3 24
$1.1B
$7.9B
Q2 24
$1.1B
$7.9B
Q1 24
$1.1B
$7.8B
Total Assets
DNOW
DNOW
RVTY
RVTY
Q4 25
$3.9B
$12.2B
Q3 25
$1.7B
$12.1B
Q2 25
$1.7B
$12.4B
Q1 25
$1.7B
$12.4B
Q4 24
$1.6B
$12.4B
Q3 24
$1.6B
$12.8B
Q2 24
$1.6B
$13.4B
Q1 24
$1.6B
$13.4B
Debt / Equity
DNOW
DNOW
RVTY
RVTY
Q4 25
0.18×
Q3 25
Q2 25
Q1 25
Q4 24
0.00×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DNOW
DNOW
RVTY
RVTY
Operating Cash FlowLast quarter
$83.0M
$182.0M
Free Cash FlowOCF − Capex
$76.0M
$161.8M
FCF MarginFCF / Revenue
7.9%
21.0%
Capex IntensityCapex / Revenue
0.7%
2.6%
Cash ConversionOCF / Net Profit
1.85×
TTM Free Cash FlowTrailing 4 quarters
$134.0M
$509.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DNOW
DNOW
RVTY
RVTY
Q4 25
$83.0M
$182.0M
Q3 25
$43.0M
$138.5M
Q2 25
$45.0M
$134.3M
Q1 25
$-16.0M
$128.2M
Q4 24
$122.0M
$174.2M
Q3 24
$74.0M
$147.9M
Q2 24
$21.0M
$158.6M
Q1 24
$81.0M
$147.6M
Free Cash Flow
DNOW
DNOW
RVTY
RVTY
Q4 25
$76.0M
$161.8M
Q3 25
$39.0M
$120.0M
Q2 25
$41.0M
$115.5M
Q1 25
$-22.0M
$112.2M
Q4 24
$119.0M
$149.8M
Q3 24
$72.0M
$125.6M
Q2 24
$18.0M
$136.6M
Q1 24
$80.0M
$129.7M
FCF Margin
DNOW
DNOW
RVTY
RVTY
Q4 25
7.9%
21.0%
Q3 25
6.2%
17.2%
Q2 25
6.5%
16.0%
Q1 25
-3.7%
16.9%
Q4 24
20.8%
20.5%
Q3 24
11.9%
18.4%
Q2 24
2.8%
19.7%
Q1 24
14.2%
20.0%
Capex Intensity
DNOW
DNOW
RVTY
RVTY
Q4 25
0.7%
2.6%
Q3 25
0.6%
2.6%
Q2 25
0.6%
2.6%
Q1 25
1.0%
2.4%
Q4 24
0.5%
3.4%
Q3 24
0.3%
3.3%
Q2 24
0.5%
3.2%
Q1 24
0.2%
2.7%
Cash Conversion
DNOW
DNOW
RVTY
RVTY
Q4 25
1.85×
Q3 25
1.72×
2.97×
Q2 25
1.80×
2.49×
Q1 25
-0.73×
3.03×
Q4 24
6.10×
1.84×
Q3 24
5.69×
1.57×
Q2 24
0.88×
2.87×
Q1 24
3.86×
5.67×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DNOW
DNOW

Pipelines$455.0M47%
Downstream And Industrial$196.0M20%
Gas Utilities$183.0M19%
Oil And Gas Properties$105.0M11%
Other$20.0M2%

RVTY
RVTY

Immunodiagnostics$240.8M31%
Life Sciences$191.4M25%
Reproductive Health$149.3M19%
Segment Operating Income$132.0M17%
Software$62.3M8%

Related Comparisons